耐利福平结核短程治疗中获得性耐药研究
该研究嵌套于中国TB-TRUST系列短程治疗试验,纳入114例耐利福平结核患者,采用全基因组测序检测获得性耐药。16例(14.0%)发生至少一次获得性耐药事件,吡嗪酰胺最常见(8.6%),治疗依从性差者获得性耐药更频繁(31.1% vs 11.2%,p=0.048)。
要点
- 短程治疗耐利福平结核获得性耐药发生率14.0%,以吡嗪酰胺和贝达喹啉为主。
- 治疗依从性差者获得性耐药风险显著更高(31.1% vs 11.2%,p=0.048)。
- 获得性耐药中位出现时间为治疗后17天,提示早期耐药可能反映方案效力不足。
核心结论
- 耐利福平结核短程治疗存在不可忽视的获得性耐药风险。
- 治疗依从性差可能增加获得性耐药的可能性。
- 获得性耐药早期出现可能提示方案效力欠佳。
研究设计与样本
- 研究嵌套于中国TB-TRUST系列耐利福平结核短程治疗试验。
- 纳入至少两株分离株完成全基因组测序的114例参与者。
- 无氟喹诺酮及二线注射药耐药者接受不含贝达喹啉的口服方案或WHO推荐的含注射药方案。
- 氟喹诺酮耐药者接受含贝达喹啉的口服方案。
主要发现
- 114例中16例(14.0%;95% CI,8.8-21.6%)发生至少一次获得性耐药事件,共17次事件。
- 获得性耐药中位出现时间为治疗开始后17天(范围,14-605天)。
- 吡嗪酰胺获得性耐药6/70(8.6%;95% CI,4.0-17.5%),贝达喹啉5/111(4.5%;95% CI,1.9-10.1%)。
- 乙胺丁醇2/48(4.2%;95% CI,1.2-14.0%),氟喹诺酮4/100(4.0%;95% CI,1.6-9.8%),氯法齐明4/111(3.6%;95% CI,1.4-8.9%)。
- 利奈唑胺和环丝氨酸未检测到获得性耐药;13例细菌学失败者中2例发现获得性耐药。
关键数值与推荐
- 获得性耐药通过全基因组测序在预设耐药相关基因面板中识别突变确定。
- 治疗依从性差者获得性耐药发生率31.1%(5/16),依从性良好者11.2%(11/98),p=0.048。
临床怎么用
- 短程治疗耐利福平结核期间应监测获得性耐药,尤其关注吡嗪酰胺和贝达喹啉。
- 应加强治疗依从性管理以降低获得性耐药风险。
- 早期出现获得性耐药需评估方案效力,必要时调整治疗。
局限性
- 研究嵌套于特定试验,样本量有限。
- 获得性耐药与治疗结局的临床关联尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Shorter regimens represent a significant advancement for rifampicin-resistant tuberculosis (RR-TB) treatment. However, data on acquired drug resistance (ADR) remain limited. METHODS: This study was nested within TB-TRUST serial trials for shorter treatment for RR-TB in China. Participants without resistance to fluoroquinolone and second-line injectable drugs received either a bedaquiline-free oral regimen or the WHO-recommended injectable-containing regimen. Participants with fluoroquinolone resistance were treated with a bedaquiline-based oral regimen. All participants with two or more isolates successfully sequenced by whole-genome sequencing were included in this study. ADR was determined using whole-genome sequencing data by identifying mutations in a predefined panel of resistance-associated genes. RESULTS: Among 114 participants included, 16 (14.0%; 95% CI, 8.8-21.6%) experienced at least one ADR event (17 events in total), with a median onset of 17 (range, 14-605) days from treatment initiation. ADR was most common for pyrazinamide (6/70, 8.6%; 95% CI, 4.0-17.5%), followed by bedaquiline (5/111, 4.5%; 95% CI, 1.9-10.1%), ethambutol (2/48, 4.2%; 95% CI, 1.2-14.0%), fluoroquinolones (4/100, 4.0%; 95% CI, 1.6-9.8%), and clofazimine (4/111, 3.6%; 95% CI, 1.4-8.9%). No ADR was detected for linezolid or cycloserine. ADR was more frequent in participants with poor treatment adherence (31.1% (5/16) vs. 11.2% (11/98), p 0.048). Among 13 participants with bacteriological failure, ADR was identified in two cases. CONCLUSIONS: Shorter treatment for RR-TB carries a non-negligible risk of ADR. Poor adherence might increase the likelihood of ADR, and early emergence of ADR may indicate suboptimal regimen potency. Continued surveillance is warranted, and further studies are needed to evaluate the clinical association between ADR and treatment outcomes.
引用
- Chen X, Cai C, Song L, et al. Acquired resistance during short-course treatment for rifampicin-resistant tuberculosis. Clin Microbiol Infect. 2025. PMID: 41197899. doi:10.1016/j.cmi.2025.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。